The company’s strategic investment in FPP Holding marks a significant milestone, strengthening its position in the US market. The exchange of knowledge and access to FPP's distribution network will enhance competitiveness and growth potential.

The company has delivered stellar returns of 164.3 per cent in the last 3 years. Additionally, it maintains a ROCE of 23.8 per cent and a ROE of 20.4 per cent. Moreover, the company has a dividend yield of 36.5 per cent.

The company has delivered outstanding returns, achieving an impressive 45.35 per cent return in the past 1 year and a significant 516.32 per cent return over the last 3 years. 

On Monday, it is expected that the market will open slightly higher based on the indication from the SGX Nifty. The broader index is anticipated to begin with a positive note, showing a gain of 88.5 points after initiating the session at 18,715.

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.

The acquisition enhances their ability to address client needs and add significant value to their UK business by bringing in marquee client relationships and innovative service delivery and customer engagement models through Microsoft’s Business Applications. 

Based on the SGX Nifty's indication of a positive start for the broader index, with a gain of 70.5 points, it is expected that the market will open slightly higher on June 2. The SGX Nifty opened the session at 18,622.

The company has 3-year sales growth of 14 per cent (CAGR) and profit growth of 22 per cent (CAGR) for the last 3 years.

The company has a ROCE of 146 per cent and a ROE of 106 per cent.

Wednesday’s trading frenzy was fueled by a delightful influx of MSCI-related flows, injecting a cool USD 550 million into the market.